Neovasc (NASDAQ:NVCN) Downgraded by Bloom Burton

Bloom Burton cut shares of Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) from a buy rating to a hold rating in a research note published on Wednesday, PriceTargets.com reports.

NVCN has been the subject of a number of other research reports. HC Wainwright downgraded Neovasc from a buy rating to a neutral rating in a report on Wednesday. StockNews.com initiated coverage on shares of Neovasc in a research report on Monday, January 16th. They set a sell rating on the stock.

Neovasc Stock Down 0.5 %

Shares of NASDAQ:NVCN opened at $27.70 on Wednesday. Neovasc has a fifty-two week low of $4.59 and a fifty-two week high of $28.28. The company has a quick ratio of 8.13, a current ratio of 8.44 and a debt-to-equity ratio of 0.43. The firm’s 50-day simple moving average is $13.13 and its 200-day simple moving average is $9.00. The company has a market cap of $75.98 million, a price-to-earnings ratio of -2.25 and a beta of 1.72.

Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) last released its earnings results on Thursday, November 10th. The medical equipment provider reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.82) by ($0.18). The business had revenue of $0.92 million for the quarter, compared to analyst estimates of $1.00 million. Neovasc had a negative return on equity of 78.98% and a negative net margin of 1,077.37%. As a group, equities research analysts predict that Neovasc will post -11.95 earnings per share for the current year.

Neovasc Company Profile

(Get Rating)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.

See Also

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.